A share price of Chemomab Therapeutics Ltd ADR [CMMB] is currently trading at $1.22, up 1.67%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CMMB shares have gain 1.44% over the last week, with a monthly amount drifted -12.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Chemomab Therapeutics Ltd ADR [NASDAQ: CMMB] stock has seen the most recent analyst activity on May 13, 2024, when Maxim Group initiated its Buy rating and assigned the stock a price target of $4. Previously, Oppenheimer upgraded its rating to Outperform on May 06, 2024, and kept the price target unchanged to $6.
Chemomab Therapeutics Ltd ADR experienced fluctuations in its stock price throughout the past year between $0.87 and $2.55. Chemomab Therapeutics Ltd ADR [NASDAQ: CMMB] shares were valued at $1.22 at the most recent close of the market.
Analyzing the CMMB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is -1.01 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1300 points at the first support level, and at 1.0400 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2800, and for the 2nd resistance point, it is at 1.3400.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Chemomab Therapeutics Ltd ADR [NASDAQ:CMMB] is 5.33. Further, the Quick Ratio stands at 5.33, while the Cash Ratio is 1.89.
Transactions by insiders
Recent insider trading involved OrbiMed Israel Partners Limite, Owner, that happened on Sep 12 ’24 when 0.5 million shares were purchased.
